Yurin O, Kravchenko A, Gorbachova E, Pokrovsky VV; International Conference on AIDS.
Int Conf AIDS. 1998; 12: 101 (abstract no. 12438).
Russian Aids Centre, Moscow, Russia.
OBJECTIVES: As both combination therapy and monotherapy by AZT is inaccessible for the many of HIV+ patients it still remaines essential to work out a cheaper treatment for those patients. DESIGN: Prospective, controlled study. METHODOLOGY: The clinical and immunological observation during 48 weeks for 3 groups of HIV+ adults, 116 patients of groups 1 and 2 received AZT in the daily doze of 0.6 g. 69 patients (group 1) were treated by interrupted course (treatment within every 12 weeks at 12 weeks intervals) and 47 patients (group 2) by continuous course. 52 patients (group 3) refused to receive any antyretroviral therapy. All of 168 patients were in clinical categoria A2 by CDC classification. RESULTS: The conversion to clinical categories B during the period of observation was found in 6 (8.6%) patients of group I and in 5 (10.4%) of group 2, 5 (15/6%) (p > 0.05). TABULAR DATA, SEE ABSTRACT VOLUME. Increase of the number of CD4+ cells in 13 weeks of treatment in groups 1 and 2 and decrease of this number in group 3 was statisticaly reliable. The difference in the number of CD4+ cells between patients of groups I and 2 was statisticaly reliable on the 36 weeks of observation only. CONCLUSION: The effectivity (delay in clinical progression and CD4-lymphocytes level decrease) of more cheap interrupted and standard continuous courses of AZT therapy in patients with asymptomatic HIV-infection is practicaly the same. Thus, the use of interrupted AZT therapy course gives a possibility of treatment of larger quantity of patients for same price.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Adult
- CD4-Positive T-Lymphocytes
- HIV Infections
- HIV Seropositivity
- Health Care Costs
- Humans
- Longitudinal Studies
- Prospective Studies
- Zidovudine
- economics
- methods
Other ID:
UI: 102227466
From Meeting Abstracts